Showing results (81-90 of 279) with videos related to

Sort By:
Pageof 28
Cancer|April 11, 2012
Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancerAndrew J Weickhardt, Micol S Rothman, Smita Salian-Mehta, et al.
Clinical Lung Cancer|March 11, 2022
Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical ReviewAlexis Cortot, Xiuning Le, Egbert Smit, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 11, 2010
Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatmentD Ross Camidge, Scott A Kono, Antonella Flacco, et al.
Current Medical Research and Opinion|July 11, 2022
Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1LKaren L Reckamp, Huamao M Lin, Holly Cranmer, et al.
JTO Clinical and Research Reports|August 13, 2025
Early Weight Gain as a Risk Factor for Increased Maximum Weight Gain Among Patients With NSCLC on Lorlatinib and Other ALK Tyrosine Kinase InhibitorsAlexander S Watson, Alyse W Staley, Benjamin Yoder, et al.
Plos One|February 18, 2016
Single Gene Prognostic Biomarkers in Ovarian Cancer: A Meta-AnalysisScooter Willis, Victor M Villalobos, Olivier Gevaert, et al.
The Oncologist|July 5, 2022
Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United StatesMohammad Jahanzeb, Huamao M Lin, Yanyu Wu, et al.
Clinical Lung Cancer|August 13, 2013
Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancerEamon M Berge, Xian Lu, Delee Maxson, et al.
Advances in Radiation Oncology|June 13, 2024
The Role of Local Therapy for Oligo-Progressive Disease in Oncogene-Addicted Non-Small-Cell Lung CancerDavid Chun Cheong Tsui, Douglas E Holt, Tejas Patil, et al.
Lung Cancer (Amsterdam, Netherlands)|January 10, 2025
Genomic analysis of comprehensive next generation sequencing data to explore the criteria for MET amplification as an actionable biomarker in NSCLCDavid Chun Cheong Tsui, Jessica K Lee, Candice Francheska B Tambaoan, et al.
Pageof 28